OneMedForum Now Streaming Live!
I encourage everyone to check out the live broadcast of the OneMedForum, taking place today and tomorrow, 8AM – 5PM PST! The OneMedForum highlights the […]
Articles by Doug Cress
Insight Dx Prostate Profile: Clarient Launches Gene Expression Test for Prostate Cancer
Clarient has launched a new gene expression diagnostic for prostate cancer, the Insight Dx Prostate Profile (Insight). The test, developed in conjunction with Health Discovery […]
World Heart Submits IDE Application for Levacor VAD
World Heart Corporation has submitted an FDA Investigational Device Exemption application for a pivotal bridge-to-transplant study of its Levacor Ventricular Assist Device (VAD). Ventricular assist […]
[Quick Take] Interview with Tom Bjerg Lauritzen, President & CEO of Vivostat
The Vivostat System is an automated system for the on-site preparation and application of patient-derived fibrin sealant or platelet rich fibrin (PRF). It incorporates a […]
Endurance Rhythm Harnesses the Heart’s Kinetic Energy
Competition among makers of electronic medical implants is intense, and the pressure to differentiate products has led to decreased size and new power-hungry features. As […]
AngioDynamics: No Growth Expected in 2009
It’s been a roller coaster of a year for AngioDynamics. In the past, I’ve professed my high opinion of the company. I still like ANGO […]
[Quick Take] Interview with Richard Davis, Managing Director at Needham & Co.
Over the last five years, Needham & Co. has been one of the top five underwriters of IPOs in the technology industry – specifically software. […]
Endologix Q4: Smooth Sailing
Endologix, developer of Powerlink, a treatment for abdominal aortic aneurysms (AAA), posted another strong quarter. I am an unabashed fan of the company which, in […]
OneMedForum 2009: Presenting Companies Schedule
The OneMedPlace finance conference for emerging med tech companies, the OneMedForum, will be held January 13-14 in San Francisco. Our objective has been to identify […]
A Long Time Coming: Electro-Optical Sciences to Announce MelaFind Trial Results
Irvington-NY based Electro-Optical Sciences (EOS), developer of The MelaFind System, a handheld imaging device that detects melanomas at an early stage, announced last week that […]